BioWorld - Monday, January 19, 2026

Articles Tagged with ''cervical cancer''

Zai Lab acquires China rights to Seagen’s ADC Tivdak for cervical cancer

Sep. 28, 2022
By Doris Yu

Zai Lab Ltd. has agreed to pay $30 million up front to in-license from Seagen Inc. exclusive rights to the antibody-drug conjugate (ADC) Tivdak (tisotumab vedotin) in mainland China, Hong Kong, Macau and Taiwan. Seagen is also eligible to receive development, regulatory, and commercial milestone payments of undisclosed value, as well as tiered royalties on net sales of the drug in Zai’s territory.


Read More
Vial and syringe with DNA
European Society for Medical Oncology 2022

Genexine’s therapeutic DNA vaccine could extend survival in late-stage cervical cancer

Sep. 13, 2022
By Tamra Sami
Genexine Co. Ltd.’s DNA vaccine, GX-188E, showed potential in extending overall survival in patients with advanced cervical cancer in a phase II study when given in combination with Merck & Co. Inc.’s anti-PD-1 therapy, Keytruda (pembrolizumab). The Seoul, Korea-based company analyzed 60 patients with human papillomavirus (HPV)-16 or HPV-18-positive advanced cervical cancer who had progressed after standard-of-care therapy.
Read More

Regeneron-Sanofi pull Libtayo’s sBLA

Jan. 28, 2022
By Lee Landenberger and Richard Staines
Mighty Libtayo has stumbled. Because Regeneron Pharmaceuticals Inc. and Sanofi SA couldn’t find common ground with the FDA on postmarketing studies, the two are voluntarily withdrawing the sBLA for Libtayo (cemiplimab-rwlc) as a second-line treatment for advanced cervical cancer. Discussion about the matter continues outside the U.S., the companies said.
Read More